Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06254534

Lidocaine, Dexmedetomidine, Esmolol and Magnesium Effect on Optic Nerve Sheath Diameter After Laryngoscopy

Led by Haseki Training and Research Hospital · Updated on 2025-03-20

100

Participants Needed

1

Research Sites

71 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial aims to compare the effects of lidocaine, dexmedetomidine, esmolol, and magnesium on optic nerve sheath diameter and hemodynamic response to laryngoscopy. The participants will be patients determined to need intubation and general anesthesia for any elective surgery. Each participant will receive either lidocaine, dexmedetomidine, esmolol, magnesium, or none before anesthesia induction, according to randomization. The investigator will measure the optic nerve sheath diameter by ultrasonography before and after intubation. Researchers will compare the difference between optic nerve sheath diameter, systolic blood pressure, and heart rate before and after laryngoscopy and search for the most stable group. The trial aims to determine a general anesthesia induction protocol for patients sensitive to intracranial pressure changes reflected as optic nerve sheath diameter for easy monitoring.

CONDITIONS

Official Title

Lidocaine, Dexmedetomidine, Esmolol and Magnesium Effect on Optic Nerve Sheath Diameter After Laryngoscopy

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 80 years who will receive endotracheal intubation for general anesthesia
  • Patients with American Society of Anesthesiologists (ASA) Physical Status classification I to III
Not Eligible

You will not qualify if you...

  • Allergy to dexmedetomidine, esmolol, lidocaine, or magnesium
  • Uncontrolled hypertension or advanced heart failure with ejection fraction below 35%
  • Cardiac arrhythmias, especially Type 2 and 3 blocks or supraventricular arrhythmias
  • Renal failure with glomerular filtration rate below 30 or severe liver failure
  • Known acute or previous intracranial pathology or diagnosis of epilepsy
  • Predefined difficult airway examination
  • More than one attempt required for intubation or laryngoscopy lasting more than 20 seconds

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Haseki Trainig and Research Hospital

Istanbul, Turkey (Türkiye)

Actively Recruiting

Loading map...

Research Team

B

Berna Caliskan, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here